Status:
ACTIVE_NOT_RECRUITING
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
Lead Sponsor:
AbbVie
Conditions:
Psoriasis
Eligibility:
All Genders
6-17 years
Phase:
PHASE3
Brief Summary
Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. This study evaluates adverse events and change in diseas...
Eligibility Criteria
Inclusion
- -Participants who have completed participation in study M19-977 and who meet all eligibility criteria for participation in Study M19-973 will be allowed to enroll in study M19-973.
Exclusion
- -Participants who have developed any discontinuation criteria as defined in Study M19-977.
Key Trial Info
Start Date :
July 24 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2028
Estimated Enrollment :
132 Patients enrolled
Trial Details
Trial ID
NCT04862286
Start Date
July 24 2021
End Date
April 1 2028
Last Update
August 12 2025
Active Locations (41)
Enter a location and click search to find clinical trials sorted by distance.
1
UAB Department of Dermatology /ID# 252305
Birmingham, Alabama, United States, 35233
2
First OC Dermatology /ID# 226942
Fountain Valley, California, United States, 92708
3
Integrative Skin Science and Research /ID# 226108
Sacramento, California, United States, 95815
4
University of California San Diego - Rady Children's Hospital San Diego /ID# 252348
San Diego, California, United States, 92123